Earnings Call: Apellis Pharmaceuticals Q3 2024 Results Show Promise

Investing03:24 ET

Express News | RBC Capital Maintains Sector Perform on Apellis Pharmaceuticals, Lowers Price Target to $24

Benzinga11:13 ET

Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y

Zacks Nov 6 10:40 ET

Apellis Pharmaceuticals Price Target Cut to $30.00/Share From $43.00 by Wells Fargo

Dow JonesNov 6 10:24 ET · Ratings

Piper Sandler Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Cuts Target Price to $32

Moomoo NewsNov 6 08:31 ET · Ratings

Oppenheimer Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $40

Moomoo NewsNov 6 08:31 ET · Ratings